BioCryst Pharmaceuticals, Inc.

NasdaqGS:BCRX Stock Report

Market Cap: US$2.1b

BioCryst Pharmaceuticals Valuation

Is BCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of BCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BCRX ($8.48) is trading below our estimate of future cash flow value ($75.99)

Significantly Below Future Cash Flow Value: BCRX is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCRX?

Key metric: As BCRX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BCRX. This is calculated by dividing BCRX's market cap by their current earnings.
What is BCRX's PE Ratio?
PE Ratio8.1x
EarningsUS$263.86m
Market CapUS$2.13b

Price to Earnings Ratio vs Peers

How does BCRX's PE Ratio compare to its peers?

The above table shows the PE ratio for BCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.3x
AUPH Aurinia Pharmaceuticals
6.6x-3.05%US$1.9b
CPRX Catalyst Pharmaceuticals
13.8x8.70%US$3.0b
KNSA Kiniksa Pharmaceuticals International
59.9x32.80%US$3.5b
ADMA ADMA Biologics
24.9x23.17%US$3.7b
BCRX BioCryst Pharmaceuticals
8.1x19.82%US$2.1b

Price-To-Earnings vs Peers: BCRX is good value based on its Price-To-Earnings Ratio (8.1x) compared to the peer average (26.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does BCRX's PE Ratio compare vs other companies in the US Biotechs Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NVAX Novavax
3.7x-34.86%US$1.63b
RIGL Rigel Pharmaceuticals
1.5x-33.20%US$533.32m
ABEO Abeona Therapeutics
3.2x19.19%US$262.83m
KROS Keros Therapeutics
2.6x-29.41%US$222.81m
BCRX 8.1xIndustry Avg. 21.0xNo. of Companies10PE01632486480+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BCRX is good value based on its Price-To-Earnings Ratio (8.1x) compared to the US Biotechs industry average (21x).

Price to Earnings Ratio vs Fair Ratio

What is BCRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCRX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.1x
Fair PE Ratio19.2x

Price-To-Earnings vs Fair Ratio: BCRX is good value based on its Price-To-Earnings Ratio (8.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BCRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.48
US$21.30
+151.18%
29.84%US$32.00US$13.00n/a10
Mar ’27US$8.75
US$21.30
+143.43%
29.84%US$32.00US$13.00n/a10
Feb ’27US$6.58
US$21.67
+229.28%
30.15%US$32.00US$13.00n/a9
Jan ’27US$7.80
US$20.60
+164.10%
34.41%US$32.00US$9.00n/a10
Dec ’26US$7.13
US$20.40
+186.12%
33.26%US$30.00US$9.00n/a10
Nov ’26US$7.32
US$20.27
+176.95%
32.93%US$30.00US$11.00n/a11
Oct ’26US$7.37
US$16.36
+122.03%
35.75%US$30.00US$8.00n/a11
Sep ’26US$8.31
US$16.73
+101.29%
32.45%US$30.00US$11.00n/a11
Aug ’26US$7.95
US$16.64
+109.26%
31.94%US$30.00US$11.00n/a11
Jul ’26US$9.00
US$16.64
+84.85%
31.94%US$30.00US$11.00n/a11
Jun ’26US$10.75
US$16.58
+54.26%
30.89%US$30.00US$11.00n/a12
May ’26US$8.71
US$15.17
+74.13%
38.43%US$30.00US$8.00n/a12
Apr ’26US$7.25
US$14.73
+103.13%
40.02%US$30.00US$8.00n/a11
Mar ’26US$8.61
US$15.42
+79.06%
39.50%US$30.00US$8.00US$8.7512
Feb ’26US$7.90
US$15.27
+93.33%
42.44%US$30.00US$8.00US$6.5811
Jan ’26US$7.52
US$14.82
+97.05%
43.24%US$30.00US$8.00US$7.8011
Dec ’25US$7.50
US$14.64
+95.15%
43.34%US$30.00US$8.00US$7.1311
Nov ’25US$8.43
US$14.45
+71.47%
43.99%US$30.00US$7.00US$7.3211
Oct ’25US$7.38
US$14.45
+95.86%
43.99%US$30.00US$7.00US$7.3711
Sep ’25US$8.69
US$14.45
+66.34%
43.99%US$30.00US$7.00US$8.3111
Aug ’25US$7.11
US$14.00
+96.91%
46.69%US$30.00US$6.00US$7.9511
Jul ’25US$6.67
US$14.00
+109.90%
46.69%US$30.00US$6.00US$9.0011
Jun ’25US$6.46
US$14.00
+116.72%
46.69%US$30.00US$6.00US$10.7511
May ’25US$4.57
US$13.82
+202.37%
46.68%US$30.00US$6.00US$8.7111
Apr ’25US$5.05
US$13.82
+173.63%
46.68%US$30.00US$6.00US$7.2511
Mar ’25US$5.62
US$13.82
+145.88%
46.68%US$30.00US$6.00US$8.6111
US$21.3
Fair Value
60.2% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/08 03:54
End of Day Share Price 2026/03/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG
Steven SeedhouseCantor Fitzgerald & Co.